塔拉他单抗治疗一名年轻成人的大细胞神经内分泌癌：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-07-31 DOI:10.1016/j.jtocrr.2024.100712

Shetal A. Patel MD, PhD , Young Whang MD, PhD , Chaely Medley NP , Kevin Chen PharmD , Jasmine Jordan BS , Dante Bortone PhD , Benjamin Vincent MD, PhD , Jared Weiss MD

{"title":"塔拉他单抗治疗一名年轻成人的大细胞神经内分泌癌：病例报告","authors":"Shetal A. Patel MD, PhD , Young Whang MD, PhD , Chaely Medley NP , Kevin Chen PharmD , Jasmine Jordan BS , Dante Bortone PhD , Benjamin Vincent MD, PhD , Jared Weiss MD","doi":"10.1016/j.jtocrr.2024.100712","DOIUrl":null,"url":null,"abstract":"<div><p>A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 10","pages":"Article 100712"},"PeriodicalIF":3.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000821/pdfft?md5=e7a77021a0e8cd2cd380bfac2c94fab0&pid=1-s2.0-S2666364324000821-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report\",\"authors\":\"Shetal A. Patel MD, PhD , Young Whang MD, PhD , Chaely Medley NP , Kevin Chen PharmD , Jasmine Jordan BS , Dante Bortone PhD , Benjamin Vincent MD, PhD , Jared Weiss MD\",\"doi\":\"10.1016/j.jtocrr.2024.100712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 10\",\"pages\":\"Article 100712\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000821/pdfft?md5=e7a77021a0e8cd2cd380bfac2c94fab0&pid=1-s2.0-S2666364324000821-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

一名患有转移性肺大细胞神经内分泌癌的 20 岁男子接受了 delta-like ligand 3 靶向双特异性 T 细胞捕获剂 tarlatamab 的治疗。治疗过程中出现了一过性细胞因子释放综合征，但最终取得了部分疗效。双特异性T细胞捕获剂可能会为肺大细胞神经内分泌癌提供一种新的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊